{
    "organizations": [],
    "uuid": "464bb06f9a27337b0167855ecb2367be622449c0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novartis-says-expand-study-shows-s/brief-novartis-says-expand-study-shows-siponimods-efficacy-idUSFWN1RW0ZZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Novartis says EXPAND study shows siponimod's (Baf312) efficacy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20 (Reuters) - Novartis AG says:\n* EXPAND study showed siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis\n* In EXPAND, siponimod also had a meaningful benefit on patientsâ€™ cognitive processing speed Further company coverage: (Reporting By Zurich newsroom)\n ",
    "published": "2018-04-20T13:23:00.000+03:00",
    "crawled": "2018-04-21T18:27:05.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novartis",
        "ag",
        "say",
        "expand",
        "study",
        "showed",
        "siponimod",
        "baf312",
        "reduced",
        "risk",
        "disability",
        "progression",
        "largely",
        "disassociated",
        "relapse",
        "patient",
        "secondary",
        "progressive",
        "multiple",
        "sclerosis",
        "expand",
        "siponimod",
        "also",
        "meaningful",
        "benefit",
        "patient",
        "cognitive",
        "processing",
        "speed",
        "company",
        "coverage",
        "reporting",
        "zurich",
        "newsroom"
    ]
}